## WHAT IS CLAIMED IS:

- 1. A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a CCR-2 antagonist.
- 2. A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:

10 wherein:

15

20

5

X is selected from the group consisting of:

-O-, -NR<sup>20</sup>-, -S-, -SO-, -SO<sub>2</sub>-, and -CR<sup>21</sup>R<sup>22</sup>-, -NSO<sub>2</sub>R<sup>20</sup>-,

-NCOR<sup>20</sup>-, -NCO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>CO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>OCOR<sup>20</sup>-, -CO-,

where  $R^{20}$  is selected from: hydrogen,  $C_{1-6}$  alkyl, benzyl, phenyl,

C<sub>3-6</sub> cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1-6</sub> alkyl, and trifluoromethyl,

where R<sup>21</sup> and R<sup>22</sup> are independently selected from: hydrogen, hydroxy, C<sub>1-6</sub> alkyl, -O-C<sub>1-6</sub>alkyl, benzyl, phenyl, C<sub>3-6</sub> cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1-6</sub> alkyl, and trifluoromethyl;

- $R^1$  is selected from:
  - -C1-6alkyl-, -C0-6alkyl-O- $\dot{C}_{1}$ -6alkyl-, -C0-6alkyl-S-C1-6alkyl-,
  - -(C0-6alkyl)-(C3-7cycloalkyl)-(C0-6alkyl), hydroxy, -CO<sub>2</sub>R<sup>20</sup>, heterocycle,
  - -CN, -NR<sup>20</sup>R<sup>26</sup>-, -NSO<sub>2</sub>R<sup>20</sup>-, -NCOR<sup>20</sup>-, -NCO<sub>2</sub>R<sup>20</sup>-, -NCOR<sup>20</sup>-,
  - -CR $^{21}$ CO $_{2}$ R $^{20}$ -, -CR $^{21}$ OCOR $^{20}$ -, phenyl and pyridyl,

where R<sup>26</sup> is selected from: hydrogen, C<sub>1-6</sub> alkyl, benzyl, phenyl, C<sub>3-6</sub> cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1-6</sub> alkyl, and trifluoromethyl

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- 10 (c) -O-C<sub>1-3</sub>alkyl,

5

15

30

- (d) trifluoromethyl,
- (f)  $C_{1-3}$ alkyl,
- (g) -O-C<sub>1</sub>-3alkyl,
- (h)  $-CO_2R^{20}$ ,
- (i)  $-SO_2R^{20}$ ,
  - (j) -NHCOCH<sub>3</sub>,
  - (k) -NHSO<sub>2</sub>CH<sub>3</sub>,
  - (l) -heterocycle,
  - (m) = 0,
- 20 (n) -CN,

and where the phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy and trifluoromethyl;

- $R^2$  is selected from:
  - (a) hydrogen,
  - (b) hydroxy,
  - (c) halo,
  - (d) C<sub>1-3</sub>alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
  - (e)  $-NR^{20}R^{26}$ ,
  - (f)  $-CO_2R^{20}$ ,
  - (g) -CONR20R26,
  - (h) -NR20COR21,
- 35 (i) -OCONR<sup>20</sup>R<sup>26</sup>,

	·(j)	-NR20CONR20R26,
	(k)	-heterocycle,
	(1)	-CN,
	(m)	-NR <sup>20</sup> -SO <sub>2</sub> -NR <sup>20</sup> R <sup>26</sup> ,
5	(n)	-NR20-SO <sub>2</sub> -R26,
	(o)	-SO <sub>2</sub> -NR <sup>20</sup> R <sup>26</sup> , and
	(p)	=0, where $R^2$ is connected to the ring via a double bond;
	R <sup>3</sup> is selected from:	
10	(a)	hydrogen,
	(b)	hydroxy,
	(c)	halo,
	(d)	C <sub>1-6</sub> alkyl,
	(e)	-O-C <sub>1-6</sub> alkyl,
15	(f)	-NR <sup>20</sup> R <sup>21</sup> ,
•	(g)	-NR <sup>20</sup> CO <sub>2</sub> R <sup>21</sup> ,
	(h)	$-NR^{20}CONR^{20}R^{21}$ ,
	(i)	-NR20-SO <sub>2</sub> -NR20R21,
	<b>(j)</b>	-NR <sup>20</sup> -SO <sub>2</sub> -R <sup>21</sup> ,
20	(k)	heterocycle,
	(I)	-CN,
	(m)	-CONR <sup>20</sup> R <sup>21</sup> ,
	(n)	$-CO_2R^{20}$ ,
	(o)	-NO <sub>2</sub> ,
25	(p)	-S-R <sup>20</sup> ,
	(q)	-SO-R <sup>20</sup> ,
	(r)	-SO <sub>2</sub> -R $^{20}$ , and
	· (s)	-SO <sub>2</sub> -NR <sup>20</sup> R <sup>21</sup> ;
30	R <sup>4</sup> is selected from:	
	(a)	hydrogen,
	(b)	C <sub>1-6</sub> alkyl,
	(c)	trifluoromethyl,
	(d)	trifluoromethoxy,
35	(e)	chloro,

**(f)** 

fluoro,

	(g)	bromo, and
	(h)	phenyl;
5	R <sup>5</sup> is selected from:	
,	(a)	C <sub>1-6</sub> alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro
		and optionally substituted with hydroxyl,
	(b)	-O-C <sub>1-6</sub> alkyl, where alkyl may be unsubstituted or substituted with 1-6
		fluoro,
10	(c)	-CO-C1-6alkyl, where alkyl may be unsubstituted or substituted with 1-6
		fluoro,
	(d)	-S-C <sub>1-6</sub> alkyl, where alkyl may be unsubstituted or substituted with 1-6
		fluoro,
	(e)	-pyridyl, which may be unsubstituted or substituted with one or more
15		substituents selected from the group consisting of: halo, trifluoromethyl,
		$C_{1-4}$ alkyl, and $CO_2R^{20}$ ,
	(f)	fluoro,
	<b>(</b> g)	chloro,
	(h)	bromo,
20	(i)	-C4_6cycloalkyl,
	<b>(j)</b>	-O-C4_6cycloalkyl,
	(k)	phenyl, which may be unsubstituted or substituted with one or more
		substituents selected from the group consisting of: halo, trifluoromethyl,
		$C_{1-4}$ alkyl, and $CO_2R^{20}$ ,
25	(1)	-O-phenyl, which may be unsubstituted or substituted with one or more
	•	substituents selected from the group consisting of: halo, trifluoromethyl,
		$C_{1-4}$ alkyl, and $CO_2R^{20}$ ,
	(m)	-C <sub>3-6</sub> cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6
		fluoro,
30	(n)	-O-C <sub>3-6</sub> cycloalkyl, where alkyl may be unsubstituted or substituted with 1
		6 fluoro,
	(o)	-heterocycle,
	(p)	-CN, and
	(q)	$-CO_2R^{20}$ ;
35		

## R<sup>6</sup> is selected from: (a) hydrogen, (b) C<sub>1-6</sub>alkyl, and (c) trifluoromethyl 5 (d) fluoro chloro, and (e) (f) bromo; R<sup>7</sup> is selected from: 10 (a) hydrogen, and C<sub>1.6</sub>alkyl, which is unsubstituted or substituted with 1-3 substituents where (b) the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1-6</sub>alkyl, and -O-C<sub>1-3</sub>alkyl; R<sup>8</sup> is selected from: 15 (a) hydrogen, C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 (b) substituents where the substituents are chosen from the group: fluoro, C<sub>1</sub>. 3alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, fluoro, 20 (c) -O-C<sub>1-3</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-3 (d) fluoro, and C<sub>3-6</sub> cycloalkyl, (e) -O-C<sub>3-6</sub>cycloalkyl, **(f)**

25

(g) hydroxy,

(h)  $-CO_2R^{20}$ ,

(i)  $-OCOR^{20}$ ,

or R<sup>7</sup> and R<sup>8</sup> may be joined together via a C<sub>2-4</sub>alkyl or a C<sub>0-2</sub>alkyl-O-C<sub>1-3</sub>alkyl chain to form a 5-7 membered ring;

30

35

## R<sup>9</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,

- (c)  $CO_2R^{20}$ ,
- (d) hydroxy, and
- (e) -O-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,

or  $R^8$  and  $R^9$  may be joined together by a  $C_{1-4}$ alkyl chain or a  $C_{0-3}$ alkyl-O- $C_{0-3}$ alkyl chain to form a 3-6 membered ring;

## R<sup>10</sup> is selected from:

5

15

20

- 10 (a) hydrogen, and
  - (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
  - (c) fluoro,
  - (d) -O-C<sub>3-6</sub>cycloalkyl, and
  - (e) -O-C<sub>1-3</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,

or  $R^8$  and  $R^{10}$  may be joined together by a  $C_{2\text{--}3}$  alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, - $CO_2R^{20}$ ,  $C_{1\text{--}3}$  alkyl, and  $C_{1\text{--}3}$  alkoxy,

or  $R^8$  and  $R^{10}$  may be joined together by a  $C_{1\text{-}2}$ alkyl-O- $C_{1\text{-}2}$ alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, - $CO_2R^{20}$ ,  $C_{1\text{-}3}$ alkyl, and

25  $C_{1-3}$ alkoxy,

or  $R^8$  and  $R^{10}$  may be joined together by a -O-C<sub>1-2</sub>alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and

30  $C_{1-3}$ alkoxy;

n is selected from 0, 1 and 2; the dashed line represents a single or a double bond; and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

35

- 3. A method of claim 2, wherein X is oxygen.
- 4. A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:

10

5

15

20

25